Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Scenic Biotech BV ("Scenic"), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for.
/PRNewswire/ Scenic Biotech BV ("Scenic"), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for.
- Investment will accelerate Scenic Biotech's transition into a development stage company, advancing its in-house pipeline and supporting the creation of new programs based on its
- Spin-out from University of Oxford built on a decade of world-leading research on blood cancers and breakthrough innovation in single-cell multi-omic.